Where does Labrys Biologics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Labrys Biologics, Inc. ranks #32,301 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Labrys Biologics, Inc. hold?

Labrys Biologics, Inc. holds 8 US utility patents granted between 2015 and 2016, spanning 3 technology areas.

What is Labrys Biologics, Inc.'s Innovation Score?

Labrys Biologics, Inc. has an Innovation Score of 27.0 out of 100 (22nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Labrys Biologics, Inc.'s patent grant rate increasing or decreasing?

Labrys Biologics, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Labrys Biologics, Inc.'s patents?

Labrys Biologics, Inc.'s patents average 22.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Labrys Biologics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Labrys Biologics, Inc.

Q: What technology areas does Labrys Biologics, Inc. focus on?

Labrys Biologics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 3 technology areas, recorded in grant years 2015–2016. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Labrys ranks #32,301 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 3 technology areas.

#32,301
of 49,997 US assignees by volume: 22nd percentile
by Innovation Score (27.0/100): 22.1
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32301 · US Corporation #32,301 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,301/49,997
PHOTO-FINISH Lab2Fab
CPC-NARROW A61P · 3 areas
INNOV-THIN 27.0/100
CLAIMS-DENSE 22.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lab2Fab LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Labrys Biologics · this assignee

27
3D Lighting… · lowest

7

What this shows Labrys's Innovation Score is 27.0/100 (22nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Labrys's grants concentrate

Labrys Biologics, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (7 grants) versus a trough of 1 in 2015. By volume, Labrys sits between Lysulin, Inc. and LanzaTech NZ, Inc..

Lysulin

8
Lyteloop

8
Lab2fab

8
Laboratoire M2

8
Lahey Clinic

8
Laird Dabendorf

8
Landmark Screens

8
Lanzatech NZ

8
Labrys Biologics ◀

8

What this shows Labrys holds 8 patents at rank #32,337, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Labrys

By rank, the assignees closest to #32,337 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Labrys's primary technology class.

Labrys's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 22nd percentile higher than 22% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2016

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Labrys Biologics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	12.5%
2016	7	87.5%

Which technologies does Labrys Biologics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C07K - Peptides 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

Top 3 of 3 technology areas

Where it ranks

Overall rank by patents

#32,301

of 49,997 tracked assignees

Innovation Score

27.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Labrys Biologics, Inc.'s patent record in context - here's where to go next.

Labrys Biologics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #32,301 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Labrys Biologics, Inc. against Lysulin, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.